Merck KGaA: Erbitux Granted extended Use in Japan for First-Line-Treatment for mCRC-Patients with KRAS wild-type Tumors
Approval of change in product information is based on the data of the Phase III CRYSTAL trial
30-Mar-2010 -
Merck KGaA announced that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the first-line-treatment for patients with epidermal growth factor receptor (EGFR)-expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer (mCRC) carrying ...
chemotherapy
colorectal cancer
gastrointestinal cancer
+5